27 October 2023
Ropes & Gray Advises LianBio in Agreement with Bristol Myers Squibb for Heart Drug Rights in Asia
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Eric Wu Lead | Ropes & Gray | Partner | life sciences | Not stated |
| Hannah England Lead | Ropes & Gray | Partner | life sciences | Not stated |
| Zach Blume Lead | Ropes & Gray | Partner | capital markets | Not stated |
| Tom Danielski | Ropes & Gray | Partner | capital markets | Not stated |
| Katherine Wang | Ropes & Gray | Partner | life sciences | Not stated |
| Melissa Rones | Ropes & Gray | Partner | IP transactions | Not stated |
| David Saltzman | Ropes & Gray | Partner | tax | Not stated |
| Renata Ferrari | Ropes & Gray | Partner | employment & benefits | Not stated |
| Rocky Tsai | Ropes & Gray | Partner | litigation & enforcement | Not stated |
| Christine Joyce | Ropes & Gray | Other | employment & benefits | Not stated |
7 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 350m ($350 million)
- What the figure measures
- Total transaction value
- Client
- LianBioSell-side
- Counterparties
- Bristol Myers Squibb (Buy-side)